Combined REGN-COV2 Antibody Therapy Immediately Prevented a Patient with Refractory Type 1 Autoimmune Pancreatitis from Contracting SARS-CoV-2 during the Sixth Wave in Japan

Chihiro Katsuso; Kensuke Kubota; Katsushi Tanaka; Yusuke kurita; Atsushi Nakajima

doi:10.2169/internalmedicine.1421-22

CASE REPORTS

Combined REGN-COV2 Antibody Therapy Immediately Prevented a Patient with Refractory Type 1 Autoimmune Pancreatitis from Contracting SARS-CoV-2 during the Sixth Wave in Japan

Chihiro Katsuso, Kensuke Kubota, Katsushi Tanaka, Yusuke kurita, Atsushi Nakajima

Author information

Keywords: autoimmune pancreatitis, COVID19, REGN-COV2 antibody combination therapy

JOURNAL OPEN ACCESS

2023 Volume 62 Issue 12 Pages 1765-1770

DOI https://doi.org/10.2169/internalmedicine.1421-22

J-STAGE : internalmedicine 62 17 pp.2595-2595

Details

Abstract

A 51-year-old man who had been receiving steroid therapy for type 1 autoimmune pancreatitis (AIP) for 3 years contracted coronavirus disease 2019 (COVID-19). As he had a high-grade fever and dry cough, and because his SpO₂ level had dropped below 95% in the supine position, he was considered as being at a high risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); therefore, he received combined REGN-COV2 antibody therapy. The patient's fever resolved immediately after this treatment, and he went into remission. A high cumulative steroid dose is associated with an increased susceptibility to infection. Early antibody cocktail therapy may be effective and rewarding for steroid-dependent type 1 AIP patients with a potential risk for SARS-CoV-2.

Corresponding author

Register with J-STAGE for free!